Aman Vora

Hi, thanks for the opportunity. So, I will just start with where Anish left. So, congratulations on the ramp up in the Animal Health vertical and in record time. When we talk about the business, Rs. 400 crores of top line by FY30, and you mentioned that the margin profile of the business is better than that we report for the pharma division.

Okay, got that. And second is on the Crop Protection side. So, this is not only for Hikal, but for the industry too. It has almost been two years of first tepid volumes, then tepid pricing now. So, what would it take for the industry or for Hikal specifically to get back on trajectory in this business? And how do you look at, I understand FY27 would be a year of recovery and all of those things.

Right. Got that. Thanks. Sameer. Just continuing a couple of more questions from my side. So, as I hear your commentary and think about Hikal, we are positioning more like I think five, six years back, we were seen more as a chemical company or maybe a decade back. Now, if I think about next five years, we are positioning ourselves more as a pharma company. Is my understanding correct?